Finance Biotech Stock Entrada Surges On $250 Million Muscular Dystrophy Deal With VertexDecember 8, 20220 Entrada Therapeutics (TRDA) inked a $250 million cope with Vertex Prescribed drugs (VRTX) to develop a muscular dystrophy drug, and…
